Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.
Reduced usage of antipsychotics in first-episode psychosis was associated with improved executive functioning.
Study finds that 74% of patients with a psychotic disorder off antipsychotics at end of 10 years are in remission.
Researchers recommend that healthcare professionals be vigilant regarding the signs of respiratory failure among patients with COPD who are receiving antipsychotics, especially during the initial treatment phase.
Researchers believe that side-effect monitoring is critical because of the increase in the use of antipsychotics
A review of the scientific literature related to the withdrawal of antipsychotics: animal studies, withdrawal symptoms, tapering success rates, and consumer accounts of discontinuation.
Association found between long-term antipsychotic use and poorer performance on cognitive tasks in adults diagnosed with ‘schizophrenia.’
Patients who recover from a single episode of psychosis are often prescribed antipsychotics long-term, despite a lack of evidence for this practice
The researchers find that the drug effects for reducing psychosis are small and that treatment failure and severe side effects are common.
This guide, by psychiatrists Volkmar Aderhold and Peter Stastny, provides a comprehensive review of antipsychotics and an evidence-based rationale for avoiding their use in first-episode psychosis, and for minimizing their long-term use.
Long-term treatment with antipsychotic drugs is currently considered the standard treatment for patients diagnosed with ‘schizophrenia.’ A new study challenges this practice, however. The...
This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.
A new study published this month in the journal Neuron identifies the mechanism by which antipsychotic drugs can induce parkinsonism, a condition involving movement...
A systematic review published this week in the British Journal of Clinical Pharmacology found that patients taking antipsychotic drugs were at nearly twice the risk...
The US FDA has issued a new warning for the atypical antipsychotic Olanzapine, also known by the brand names Zyprexa and Symbyax. The agency...
Yesterday, the US Food and Drug Administration (FDA) released a warning that the antipsychotic drug aripiprazole or Abilify is associated with compulsive and uncontrollable...
A new study in JAMA Neurology finds that the use of antipsychotic drugs more than doubled the risk of death in patients with Parkinson’s...
In a study published yesterday, researchers from the Nippon Medical School in Tokyo bring attention to a condition known as neuroleptic-induced deficit syndrome (NIDS)...
In a featured article for Psychiatric Services, psychiatrists from Dartmouth raise the alarm on the increasing numbers of children prescribed dangerous antipsychotic drugs. Despite the fact that data on the safety of long-term use of these drugs in this vulnerable population “do not exist,” the rate of children and adolescents being prescribed antipsychotic drugs have continued to increase over the past fifteen years.
Researchers from the City College of New York and Columbia University published a study this month testing the hypothesis that people diagnosed with schizophrenia treated long-term with antipsychotic drugs have worse outcomes than patients with no exposure to these drugs. They concluded that there is not a sufficient evidence base for the standard practice of long-term use of antipsychotic medications.
More than ten-percent of adults in the United States are currently prescribed at least one psychiatric medication but there is currently a lack of research on the prevalence of adverse drug events (ADEs) associated with these prescriptions outside of clinical trials.
The percentage of seniors in the United States prescribed potentially deadly antipsychotic drugs increases with age. A new study reveals that in the face of serious risks of strokes, fractures, kidney injuries, and death, over seventy-five percent of seniors given antipsychotics do not have a diagnosis for a mental disorder.
Results of a large government-funded study call into question current drug heavy approaches to treating people diagnosed with schizophrenia. The study, which the New York Times called “by far the most rigorous trial to date conducted in the United States,” found that patients who received smaller doses of antipsychotic drugs with individual talk therapy, family training, and support for employment and education had a greater reduction in symptoms as well as increases in quality of life, and participation in work and school than those receiving the current standard of care.
New research published in the July issue of The Journal of Clinical Psychiatry found that the use of mood stabilizers, antipsychotics, antidepressants, and hypnotics during pregnancy is associated with increased health risks to the infant.
New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”